Neuronetics Expands Access to TMS Therapy for Mental Health

Neuronetics Enhances Access to Mental Health Treatment

MALVERN, Pa. — Neuronetics, Inc. (NASDAQ: STIM) has made significant strides in expanding access to transcranial magnetic stimulation (TMS) therapy, particularly for individuals facing major depressive disorder (MDD). The medical technology company, dedicated to advancing neurohealth treatments, announced updates to various payors who are now more willing to cover TMS therapy. This is crucial for patients who have not found relief through traditional medication.

New Insurance Policies for Adolescents and Adults

As part of this initiative, BlueCross BlueShield (BCBS) of North Carolina has recently expanded its TMS policy to include adolescents aged 15 years and older. This change followed the recent FDA clearance for NeuroStar, establishing it as the first and only TMS treatment authorized specifically for adolescents. Such moves are expected to significantly impact the well-being of more than 2.2 million lives covered under BCBS in North Carolina.

Louisiana Medicaid Joins the Movement

Additionally, Louisiana Medicaid now covers TMS therapy for adults aged 18 and above. This coverage marks the beginning of TMS treatment options for adults in Louisiana, a state where over 1.6 million lives will be affected by this new policy.

CEO Comments on Policy Changes

Keith J. Sullivan, President and CEO of Neuronetics, expressed enthusiasm regarding these developments, stating, "We are thrilled to see expanded health policies that increase access to NeuroStar TMS Therapy for depression. This reflects a critical advancement, particularly as payors recognize the pressing demand for effective mental health treatments. Our goal is to support patients, especially in light of the current shortage of mental health providers."

A Momentum of Change

These policy changes signal a broader trend among both commercial and governmental payers to reduce barriers related to TMS therapy. Neuronetics has previously celebrated similar policy expansions with other payors like Aetna and California Medicaid, demonstrating their commitment to improving access to mental health care.

Leading the Industry in Health Policy Advocacy

What sets Neuronetics apart is not just its advanced TMS technology but also its proactive approach to health policy advocacy. They employ a dedicated health policy team that collaborates with both healthcare providers and payors to advocate for necessary updates to coverage. This is particularly relevant as Neuronetics holds the distinction of being the only TMS company with FDA clearance for treating adolescents.

About NeuroStar TMS Therapy

Neuronetics’ NeuroStar TMS Therapy offers a non-invasive and drug-free treatment option for individuals suffering from neurohealth issues, especially those who struggle with MDD. The therapy is designed not only for adults but also accommodates adolescents aged 15-21 experiencing depressive episodes. NeuroStar has become an industry leader, delivering over 6.6 million treatments and ensuring that patients receive the quality care they deserve.

Contact Information for More Insights

For more details about NeuroStar TMS Therapy and how it can benefit individuals dealing with mental health challenges, visit www.neurostar.com. The company is committed to improving patient lives through innovative solutions and expanding access to vital mental health care.

Frequently Asked Questions

What is TMS therapy?

Transcranial Magnetic Stimulation (TMS) therapy is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain, helping to alleviate symptoms of depression.

How does Neuronetics’ NeuroStar differ from other TMS therapies?

Neuronetics’ NeuroStar is the only TMS device approved by the FDA for use in adolescents and has a dedicated team focused on health policy advocacy, enhancing access to treatments.

Who is eligible for TMS therapy?

Patients suffering from major depressive disorder, particularly those who have not responded well to traditional medication, are eligible for TMS therapy.

What impact will expanded insurance coverage have?

Expanded coverage helps remove barriers, allowing more patients to access crucial mental health treatments sooner in their care journey.

What is the commitment of Neuronetics to mental health?

Neuronetics is dedicated to providing innovative neurohealth solutions, ensuring that individuals suffering from mental health conditions have access to effective, non-invasive treatment options.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.